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Abstract
Objectives Effective strategies are needed to translate knowledge (evidence)
into practice to improve the quality of community pharmacy services. We
report the first step of a novel knowledge translation process which involved
the systematic identification and prioritisation of community pharmacy services
in Scotland which were perceived to require improvement and/or guideline
development.
Methods This process involved three stages and a stakeholder group compris-
ing community pharmacists, policy makers, lay and pharmacy organisation rep-
resentatives. A modified nominal group technique (NGT) was used for topic
generation (August 2013) followed by an electronic Delphi survey (eDelphi),
October–December 2013) and topic rationalisation (December 2013) based on
feasibility, acceptability, and potential impact for practice improvement.
Key findings In total, 63 items were identified during the modified NGT which
were categorised into 20 topics to form the starting point of the eDelphi. In
total, 74 individuals (mostly community pharmacists) indicated an interest in
the eDelphi, which achieved response rates of 63.5%, 67.6%, and 70.3%,
respectively in Rounds 1, 2, and 3. Consensus was achieved with six topics:
promoting the appropriate sale and supply of over-the-counter medicines;
patient counselling for prescribed medication; pharmaceutical care to promote
medication adherence; promotion and delivery of a Minor Ailment Scheme;
pharmaceutical care of vulnerable patients; and effective use of community
pharmacy workforce. Of these, the priority topic selected for the next stage of
the programme was promoting the appropriate sale and supply of over-the-counter
medicines.
Conclusions This study adopted a systematic, inclusive, and rapid approach to
identify priorities for community pharmacy practice improvement in Scotland.
Introduction
The delivery of safe and high-quality health care services
is challenging,[1,2] and the translation of research findings
into practice is inconsistent.[2,3] Obstacles to implementa-
tion can arise at multiple levels of health care delivery:
patient, provider, policy, and/or the larger system or envi-
ronment in which the organisations are embedded.[4–6]
The critical role of implementation research (also referred
to as knowledge translation and/or improvement science)
is gaining increasing recognition with health service
researchers wishing to translate research findings into
meaningful patient care outcomes.[7–9]
National Health Service (NHS) Education for Scotland
(NES) offers a wide range of education and training sup-
port for clinical and non-clinical staff who work in
National Health Service (NHS), Scotland.[10] Since 2008,
NES has funded a major, national programme called
‘Translation Research in a Dental Setting (TRiaDS)’.[11]
The TRiaDS programme has established a practical evalu-
ative framework for the translation of guidance through
the conduct of a multidisciplinary programme of transla-
tion research.[11] This programme supports the three
quality ambitions: safe, effective, and person-centred
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care.[12] It involves a multidisciplinary team comprising
health care professionals, policy makers, guidance devel-
opers, and international experts from a range of research
disciplines such as health economics, health psychology,
and health services research. Due to the success of
TRiaDS, NES expanded the research programme to
include community pharmacy and community optometry
in 2013. The TRiaDS approach was used to meet the
overall aim of the TRiaDS in Pharmacy (TRiaDS-P) pro-
gramme, i.e. to translate research findings into meaningful
patient care outcomes. Unlike community dentistry in
Scotland, there are no specific clinical guidelines for com-
munity pharmacy practice. Therefore, the aim of this
study was to systematically identify and prioritise commu-
nity pharmacy services in Scotland which required
improvement and/or guideline development.
Method
Design of the study
The prioritisation study was undertaken as a three-stage
process involving a modified nominal group technique
(NGT)[13,14] with key stakeholders; an electronic Delphi
(eDelphi) survey; and rationalisation of priority topics.
The NGT and Delphi are commonly used in pharmacy
practice research to achieve consensus.[15] A modified
NGT was used in this current study to generate topics in
a fast and efficient manner during a face-to-face meeting.
Stage 1: key stakeholders: topic generation
using the nominal group technique
Key stakeholders, representing the Royal Pharmaceutical
Society in Scotland and the Scottish Government’s Phar-
macy & Prescribing Support Unit, were identified through
professional and personal networks. A face-to-face stake-
holder meeting was held in August 2013. The meeting
comprised a brief introduction to the purpose and goals
of the event followed by a modified NGT to identify pri-
ority topics.
The modified NGT involved each participant indepen-
dently generating topics in response to the question
‘What do you think are the priority topics/areas for com-
munity pharmacy practice improvement’. Each participant
contributed one topic to each round of the process until
topic generation was exhausted. No discussion was per-
mitted during this stage; only clarification of the meaning
of the topic was sought if necessary. This process max-
imised the number of topics generated and increased the
richness of the data collected.[16,17] The key stakeholders
then discussed the topics and formulated them into
common themes.
Stage 2: the Delphi survey
The purpose of the Delphi process[18] was to develop con-
sensus amongst a wider group of stakeholders regarding
the topics generated during Stage 1. An eDelphi was con-
ducted using the NES portal and Questback (https://www.
questback.com/uk/) to facilitate timely response. Three
rounds were undertaken.
Participants and recruitment
Delphi panel members were identified using two meth-
ods. Firstly, research team and Professional Advisory
Group members generated a list of senior community
pharmacists, representatives from pharmacy organisa-
tions, policy makers, academics, and researchers
(n = 31). The members of the key stakeholder group
were also eligible to participate. The second method
involved an email invitation being sent via the NES por-
tal to all community pharmacists who had previously
attended an NES training event (2342 individuals of
whom 1450 were ‘community pharmacy employees’, 487
were community pharmacy locums, and 203 were com-
munity pharmacy owners). Recipients were requested to
respond to the invitation if they were willing to partici-
pate in the eDelphi.
Process of determining priorities
The topics generated in Stage 1 formed the basis of the
first eDelphi round and were presented in random order.
Participants were asked to rate the importance of each
topic as a priority for guideline development and/or prac-
tice improvement using a 7-point Likert scale (1 = not
important at all to 7 = extremely important). Likert
points 2–6 were unlabelled, i.e. they were presented in a
numerical format only. Demographic data were collected
including sex, age, NHS board, employment status, type
of pharmacy sector, type, and size of pharmacy. During
this first round, respondents could add new topics to the
existing list if they considered them to be priorities.
Anonymised results from each round were fed back to
the entire cohort for the subsequent rounds with a 2-week
deadline for responses. The median score from each
round was presented alongside each topic to provide par-
ticipants in Rounds 2 and 3 with information about the
collective opinion. An email reminder was sent for
Rounds 2 and 3 one week prior to the deadline along
with a link to the survey to maximise response rates. In
Round 1, consensus was defined using the median score
with topics that achieved a median score >5 for inclusion
in Round 2. For Rounds 2 and 3, an a priori decision was
made to invoke a cut-off of the 25th percentile, i.e. ≥6,
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for eligibility for inclusion in the subsequent round/final
priority list. In Round 3, participants were asked to indi-
cate whether national guidance was available on the topic
at the time of the survey and provide details.
Analysis
Summary statistics (mean, standard deviation, median,
and interquartile range) were calculated for topics
included in each round.
Stage 3: prioritisation of identified topics
The list of topics identified from the Delphi survey was
presented to the TRiaDS Implementation Science Group
(a multidisciplinary collaboration of international experts
in implementation research) (Table S1) and the TRiaDS
Professional Advisory Group [comprising the Assistant
Director of Pharmacy (NES), an experienced community
pharmacist, and a Policy and Development Pharmacist
from Community Pharmacy Scotland] for discussion at
the biannual TRiaDS meeting in December 2013. Topics
were firstly mapped onto the Prescription for Excellence
Strategy[21] (for the purpose of assessment and reducing
the number of topics); which were then further assessed
based on the aim of the study (feasibility, acceptability,
and potential impact for practice improvement). The
topics selected at this meeting were then discussed with
the Chief Pharmacist (Scotland) to seek final approval of
the topic for further investigation within the time frame
of TRiaDS-P initiative.
Ethical approval
The UK Governance Arrangements for Research Ethics
Committees (GAfREC) made exemptions in 2011, and
research involving NHS staff as participants by virtue of
their professional role was excluded from the normal
remit of NHS Research Ethics Committees.[19] As such,
ethical approval was not required for this study.
Results
Stage 1: key stakeholders: topic generation
Eight (a Director of Pharmacy, Lead Pharmacist of Pri-
mary & Community Care from a Health Board, Royal
Pharmaceutical Society Practice and Policy Lead Scotland,
a research lead for the pharmacy and prescribing support
unit, a Policy & Development Pharmacist from Commu-
nity Pharmacy Scotland, a Head of Pharmacy, a commu-
nity pharmacist and a lay representative) of the 10
invitees attended the key stakeholder meeting. In total, 63
topics were generated which were then rationalised and
combined, giving a final list of 20 topics.
Stage 2: the Delphi survey
The Delphi survey was conducted over 6 weeks (October
to December 2013). In total, 74 individuals (key stake-
holders (n = 8/8, 100%); members of the wider stake-
holder group (n = 10/31, 32%); and community
pharmacists (n = 56/~2342, 0.2%) indicated interest in
participating. Of these, 28 community pharmacists were
respondents in Rounds 1 and 2 and 26 in Round 3
(Table 1), most of whom were women, aged 50–59 years
and worked in large multiples as employee pharmacists
(Table S2).
Round 1
The 20 topics from Stage 1 were included in Round 1
(Table 2). In total, 47/74 (63.5%) individuals participated.
Consensus was achieved with 17 topics, and the topics
with the highest median score of 7.0 were as follows: pa-
tient counselling for prescribed medication; promoting the
appropriate sale and supply of over-the-counter (OTC)
medicines; and promotion and delivery of the Minor Ail-
ment Scheme (MAS).1 The 17 items were then added to
Round 2 together with eight new topics identified by
Round 1 participants (pharmaceutical care of cancer;
chronic obstructive pulmonary disease (COPD); asthma;
dermatology; sexual health; improving medication adher-
ence; pharmaceutical needs assessment; and pharmacovigi-
lance).
Round 2
The response rate for Round 2 was 67.6% (50/74), with
the majority (82.0%, n = 41) having taken part in Round
1. The topics (n = 23) included in this round and the
results are presented in Table 3. Consensus was achieved
with seven topics, three of which achieved a median score
of 7.0: promoting the appropriate sale and supply of OTC
medicines; patient counselling for prescribed medication;
and pharmaceutical care to promote medication adherence.
One of the seven prioritised topics was a duplicate, i.e.
pharmaceutical care to promote medication adherence, and
improving medication adherence, and was removed from
the list leaving six topics for inclusion in Round 3.
Round 3
The Round 3 response rate was 70.3% (52/74); 90.4%
(n = 47) of these participants participated in Rounds 1
and 2. All six topics achieved highest score of median
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(7.0) and interquartile range (IQR = 7) (Table 4) and
indicated the equal importance of these topics. Of these
topics, four (promoting the appropriate sale and supply of
OTC medicines; patient counselling for prescribed medica-
tion; pharmaceutical care to promote medication adherence;
and promotion and delivery of the Minor Ailment Scheme)
had a median score of 7.0 and two (pharmaceutical care
of vulnerable patients; effective use of community pharmacy
workforce) had a median score of 6.0 in Round 2.
Stage 3: prioritisation of identified topics
All six topics were assessed at the TRiaDS meeting. The
topic effective use of community workforce cuts across all
priority topics and therefore, it was proposed to be incor-
porated into each of the priority topics selected to
undergo the TRiaDS process. The topics pharmaceutical
care for medication adherence and patient counselling for
prescribed medication were combined, because it was
believed that any interventions developed to influence
counselling would ultimately seek to achieve enhanced
medication adherence. Finally, the four topics (promoting
the appropriate sale and supply of OTC medicines, promo-
tion and delivery of the MAS, pharmaceutical care to pro-
mote medication adherence via patient counselling, and
pharmaceutical care of vulnerable patients) were prioritised
based on the Prescription for Excellence Strategy and were
further assessed based on the aim of this study. The topic
selected for the next stage of study, following the negotia-
tion stage with the chief pharmacist, was promoting the
appropriate sale and supply of OTC medicines.
Discussion
A wide range of areas for improvement was generated.
The eDelphi demonstrated consistency of views with all
six priority topics from Round 3 achieving high agree-
ment. The priority topic selected for the next part of
TRiaDS-P, promoting the appropriate sale and supply of
OTC medicine, met all criteria in terms of priorities and
therefore, it was found to be the most important topic at
the time based on the WHICH[20] and Prescription for
Excellence guidance.[21]
Engagement with stakeholders, as well as the Professional
Advisory Group and experts in implementation research,
ensured that both views of the pharmacy profession in
Scotland and multidisciplinary scientific expertise were
taken into account in the process. Identifying service-driven
priorities for practice improvement is an essential starting
point for implementation research. To our knowledge, this
is the first prioritisation study to identify topics for com-
munity pharmacy practice improvement and guideline
development. Comprehensive engagement with stakehold-
ers identified service-driven priorities. For example, the
eDelphi component was open to any community pharma-
cist within the NES database who wished to participate. All
but two of the 14 Health Board areas in Scotland were rep-
resented in each round (Table 1). However, no responses
were received from individuals in the most remote Health
Boards (NHS Orkney and NHS Western Isles) which had
seven community pharmacies (representing 0.6% of the
total number of pharmacies in Scotland) at the time of the
survey.
Table 1 Demographic characteristics of eDelphi respondents
Demographic data Round 1 Round 2 Round 3
Number of respondents (N) 47 50 52
% (n) % (n) % (n)
Gender
Female 63.8 (30) 58.0 (29) 57.7 (30)
Male 27.7 (13) 28.0 (14) 26.9 (14)
Missing response 8.5 (4) 14.0 (7) 15.4 (8)
Age (years)
18–29 10.6 (5) 8.0 (4) 7.7 (4)
30–39 6.4 (3) 10.0 (5) 7.7 (4)
40–49 36.2 (17) 28.0 (14) 26.9 (14)
50–59 38.3 (18) 38.0 (19) 40.4 (21)
>60 – 2.0 (1) 1.9 (1)
Missing response 8.5 (4) 14.0 (7) 15.4 (8)
Health board
NHS Ayrshire and Arran 2.1 (1) 2.0 (1) 1.9 (1)
NHS Dumfries and Galloway 2.1 (1) 2.0 (1) 1.9 (1)
NHS Fife 4.3 (2) 2.0 (1) 1.9 (1)
NHS Forth Valley 8.5 (4) 10.0 (5) 7.7 (4)
NHS Grampian 17.0 (8) 14.0 (7) 13.5 (7)
NHS Greater Glasgow and Clyde 25.5 (12) 24.0 (12) 26.9 (14)
NHS Highland 2.1 (1) 6.0 (3) 5.8 (3)
NHS Lothian 15.0 (7) 8.0 (4) 7.7 (4)
NHS Shetland 2.1 (1) 2.0 (1) 1.9 (1)
NHS Tayside 10.6 (5) 12.0 (6) 9.6 (5)
NHS Borders – 2.0 (1) 1.9 (1)
NHS Lanarkshire – 2.0 (1) 1.9 (1)
NHS Western Isles – – –
NHS Orkney – – –
Missing response 10.6 (5) 14.0 (7) 17.3 (9)
Pharmacy sector
Academic 8.5 (4) 8.0 (4) 5.8 (3)
Community 59.6 (28) 56.0 (28) 50.0 (26)
Primary care 19.1 (9) 18.0 (9) 1.9 (1)
Missing response 12.8 (6) 18.0 (9) 42.3 (22)
Type of community pharmacy
Independent single outlet 14.9 (7) 12.0 (6) 13.5 (7)
Large multiple (>5 pharmacies) 34.0 (16) 34.0 (17) 25.0 (13)
Small multiple (2–5 pharmacies) 4.3 (2) 8.0 (4) 7.7 (4)
Other (self-identified) 6.4 (3) 2.0 (1) 3.8 (2)
Employment status within community pharmacy
Employee 34.0 (16) 60.7 (17) 57.7 (15)
Locum 6.4 (3) 14.3 (4) 11.5 (3)
Owner 15.0 (7) 21.4 (6) 23.1 (6)
Other 4.3 (2) 3.6 (1) 7.7 (2)
Maximum values are presented in italics.
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Not all the potential participants who initially agreed to
participate in the eDelphi did so. Whilst the overall partici-
pation by community pharmacists was low, the study was
successful in obtaining high response rates across the three
rounds of Delphi survey, with the response rate increasing
with each eDelphi round. Whilst the demographic profile
of pharmacist respondents in our study is similar to a sur-
vey of registered pharmacy professionals conducted in 2013
by the General Pharmaceutical Council (GPhC) in terms of
gender, employment status, and type of pharmacy, i.e. large
multiple,[22] older pharmacists were over-represented in
our study and as such, may have influenced the results
derived.[23] The highest numbers of community pharmacy
respondents were located in NHS Health Boards Greater
Glasgow and Clyde, Lothian, and Grampian, which also
have the highest numbers of community pharmacies. How-
ever, the percentage of pharmacists who responded to eDel-
phi was comparable with the percentage of community
pharmacists working in different health boards of Scotland
(Table S3).[24]
The maximum number of participants in any round
was 52 despite 74 individuals initially indicating their
willingness to participate. The reason for the subsequent
non-response of individuals was not explored. We can
only speculate about the causes of non-response. For
example, they might have misinterpreted the purpose of
this study or perhaps considered the survey too long or
time-consuming to complete. Only one lay representative
attended Stage 1. The purpose of this study was to iden-
tify service improvement priorities from the pharmacy
profession’s perspective and as such, no further lay repre-
sentatives were involved. Involvement of lay representa-
tives in other stages of this study could have changed the
outcome of the prioritisation exercise.
The current strategy for Pharmaceutical Care in Scot-
land, Prescription for Excellence, (http://www.gov.scot/
resource/0043/00434053.pdf) was published in September
2013, i.e. after the key stakeholder meeting but prior to the
eDelphi process. Its publication is likely to have influenced
the content and outcome of this process. It is likely that pri-
orities identified now may differ from those identified by
this exercise. However, most were included in this strategy
document which continues to inform pharmacy practice in
Scotland and as such, they remain relevant.
Table 2 Results of Round 1 eDelphi
Round 1 Topic heading Mean (SD)
Interquartile range
25th
50th
(median) 75th
1. Patients counselling for prescribed medication 6.44 (0.89) 6.00 7.00 7.00
2. Promoting the appropriate sale and supply of over-the-counter (OTC) medicines 6.24 (1.35) 6.00 7.00 7.00
3. Promotion and delivery of the Minor Ailment Scheme 5.98 (1.63) 5.00 7.00 7.00
4. Pharmaceutical care to promote medication adherence [e.g. monitored
dosage system (MDS) assessment]
6.18 (0.93) 6.00 6.00 7.00
5. Effective use of community pharmacy workforce 6.09 (1.22) 6.00 6.00 7.00
6. Review of medication 5.91 (1.34) 5.00 6.00 7.00
7. Pharmaceutical care of diabetes 5.89 (1.09) 5.00 6.00 7.00
8. Community pharmacists’ role in the reduction in medicines waste 5.80 (1.32) 5.00 6.00 7.00
9. Implementation of standard operating procedures (SOPs) (e.g. repeat
dispensing, controlled drugs); national PGDs (e.g. repeat prescribing);
and referral (e.g. direct referral out of hours) processes
5.78 (1.53) 5.00 6.00 7.00
10. Pharmaceutical care of cardiovascular disease 5.76 (1.20) 5.00 6.00 7.00
11. Pharmaceutical care of vulnerable patients (including high risk,
sheltered housing residents, immigrants, homeless
5.73 (1.17) 5.00 6.00 7.00
12. Pharmaceutical care of chronic pain 5.71 (1.21) 5.00 6.00 7.00
13. Pharmaceutical care of drug misusers 5.69 (1.32) 5.00 6.00 7.00
14. Public Health Service: lifestyle behaviour services, e.g. weight
management, alcohol screening, smoking cessation
5.69 (1.27) 5.00 6.00 7.00
15. Role of pharmacist prescribing 5.22 (1.59) 4.00 6.00 7.00
16. Public Health Service: screening services for risk or early disease
detection, e.g. cancer, BP, and stroke
5.09 (1.44) 4.00 5.00 6.00
17. Pharmaceutical care of acute pain 5.04 (1.70) 4.50 5.00 6.00
18. Pharmaceutical care of acute dental problems 4.42 (1.53) 3.50 4.00 6.00
19. Antipsychotic medication use in dementia patients 4.22 (1.65) 3.00 4.00 5.00
20. Wound management 4.00 (1.31) 3.00 4.00 5.00
SD, Standard deviation.
Italics indicate topics included in Round 2.
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Table 3 Results of Round 2 eDelphi
Round 2 Topic heading Mean (SD)
Interquartile range
25th
50th
(median) 75th
Promoting the appropriate sale and supply of
over-the-counter (OTC) medicines
[Guidance regarding effective strategies to
promote the evidence-based supply of OTC]
[Round 1 median score = 7]
7.00 (0.00) 7.00 7.00 7.00
Patient counselling for prescribed medication
[Guidance regarding strategies to be adopted
by community pharmacists and/or the wider pharmacy team]
[Round 1 median score = 7]
7.00 (0.00) 7.00 7.00 7.00
Pharmaceutical care of vulnerable patients (including
high risk, sheltered housing residents, immigrants, homeless)
[Guidance regarding the contribution which
community pharmacists and/or the wider pharmacy team]
[Round 1 median score = 6]
5.92 (1.19) 6.00 6.00 7.00
Pharmaceutical care to promote medication adherence
[e.g. monitored dosage system (MDS) assessment]
[Guidance regarding evidence-based strategies to be
adopted by community pharmacists and/or the wider
pharmacy team to promote medication adherence]
[Round 1 median score = 6]
7.00 (0.00) 7.00 7.00 7.00
Promotion and delivery of the Minor Ailment Scheme
[Guidance regarding strategies for increasing the uptake
and provision of the Minor Ailment]
[Round 1 median score = 7]
6.60 (0.92) 6.75 7.00 7.00
Effective use of community pharmacy workforce
[Guidance regarding making effective use of the pharmacy
workforce to deliver safe, effective, and efficient
community pharmacy services]
[Round 1 median score = 6]
6.12 (0.87) 6.00 6.00 7.00
Improving medication adherence
[Guidance regarding the contribution which community
pharmacists and/or the wider pharmacy team can
make to enhancing medication adherence]
[Round 1 median score = 6]
6.32 (0.86) 6.00 7.00 7.00
Community pharmacist role in the reduction in medicines waste
[Guidance regarding the contribution which community
pharmacists and/or the wider pharmacy team]
[Round 1 median score = 6]
5.98 (0.82) 5.00 6.00 7.00
Implementation of standard operating procedures (SOPs)
(e.g. repeat dispensing, controlled drugs); national
patient group directions (PGDs) (e.g. repeat prescribing),
and referral (e.g. direct referral out of hours)
[Round 1 median score = 6]
5.96 (1.06) 5.00 6.00 7.00
Review of medication
[Guidance regarding safe and effective individual
reviews of patient medication]
[Round 1 median score = 6]
5.98 (1.18) 5.00 6.00 7.00
Pharmaceutical care of cardiovascular disease
[Guidance regarding the contribution which community
pharmacists and/or the wider pharmacy team]
[Round 1 median score = 6]
5.74 (0.82) 5.00 6.00 6.00
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Table 3 Continued
Round 2 Topic heading Mean (SD)
Interquartile range
25th
50th
(median) 75th
Pharmaceutical care of chronic pain
[Guidance regarding the contribution which community
pharmacists and/or the wider pharmacy team]
[Round 1 median score = 6]
5.62 (1.24) 5.00 6.00 6.00
Pharmaceutical care of diabetes
[Guidance regarding the contribution which community
pharmacists and/or the wider pharmacy team]
[Round 1 median score = 6]
5.76 (0.82) 5.00 6.00 6.00
Pharmaceutical care of drug misusers
[Guidance regarding the contribution which community
pharmacists and/or the wider pharmacy team can make
to the management and support of patients who are drug misusers]
[Round 1 median score = 6]
5.76 (1.00) 5.00 6.00 6.00
Public Health Service: lifestyle behaviour services, e.g. weight
management, alcohol screening, smoking cessation
[Guidance regarding the contribution which community
pharmacists and/or the wider pharmacy team]
[Round 1 median score = 5]
5.72 (1.29) 5.00 6.00 7.00
Role of pharmacist prescribing
[Guidance regarding the effective and efficient use of
community pharmacist prescribers]
[Round 1 median score = 6]
5.60 (1.34) 5.00 6.00 7.00
Pharmaceutical care of cancer
[Guidance regarding the contribution which community
pharmacists and/or the wider pharmacy team can make to
the care of patients with a diagnosis of cancer]
5.64 (0.85) 5.00 6.00 6.00
Pharmaceutical care of chronic obstructive pulmonary disease (COPD)
[Guidance regarding the contribution which community
pharmacists and/or the wider pharmacy team can make to
the care of patients with a diagnosis of COPD]
5.78 (0.70) 5.00 6.00 6.00
Pharmaceutical care of asthma
[Guidance regarding the contribution which community
pharmacists and/or the wider pharmacy team can make
to the care of patients with a diagnosis of asthma]
5.92 (0.75) 5.00 6.00 6.00
Pharmaceutical care of dermatology
[Guidance regarding the contribution which community
pharmacists and/or the wider pharmacy team can make
to the care of patients with dermatological conditions]
5.70 (0.93) 5.00 6.00 6.00
Pharmaceutical care of sexual health
[Guidance regarding the contribution which community
pharmacists and/or the wider pharmacy team can make
to the care of patients and/or pharmacy users in terms
of promoting and maintaining good sexual health]
5.54 (0.97) 5.00 6.00 6.00
Pharmaceutical care needs assessment
[Guidance regarding the contribution which community
pharmacists and/or the wider pharmacy team can make
to planning, conducting, or supporting pharmaceutical
care needs assessment]
5.90 (1.14) 5.00 6.00 7.00
Pharmacovigilance
[Guidance regarding the contribution which community pharmacists
and/or the wider pharmacy team can make to monitoring and
managing the safety and risks of medicines]
5.56 (1.54) 5.00 6.00 7.00
SD, Standard deviation.
Italics indicate topics included in Round 3.
International Journal of Pharmacy Practice 2018, 26, pp. 39--48 © 2017 The Authors. International Journal of Pharmacy Practice
published by John Wiley & Sons Ltd on behalf of Royal Pharmaceutical Society
Rumana S. Newlands et al. 45
Promoting the appropriate sale and supply
of over-the-counter medicines
It is likely that one of the main drivers for the identifica-
tion of ‘promoting the appropriate sale and supply of OTC
medicines’ as a priority topic was the publication of a
Which? report earlier in 2013, titled ‘Are some pharmacies
failing?’.[20] The report was published several months prior
to the prioritisation exercise. As with earlier Which?
reports, sub-optimal practice was identified across phar-
macies in relation to the sale and/or supply of different
OTC requests. This demonstrates the sensitivity of this
type of prioritisation exercise to high-profile topics within
current public and/or professional awareness. However,
sub-optimal practice with this service has been demon-
strated previously and consistently with ‘academic’ stud-
ies,[25–29] confirming that this service warrants further
attention in terms of quality improvement. Furthermore,
there is substantial evidence to suggest that the extent of
information exchange (communication) during consulta-
tions for OTC medicines is a major factor affecting the
appropriateness of these consultations.[30–35] To date, how-
ever, there has been no in-depth theory-driven exploration
of the key determinants of pharmacist and pharmacy staff
behaviour in terms of communication performance in gen-
eral and with information elicitation in particular, during
the management of these OTC consultations. As such, the
next stage of the TRiaDS-P programme will be the explo-
ration of the barriers and facilitators associated with this
behaviour using semi-structured interviews with pharma-
cists and MCAs. The interviews will be underpinned by the
Theoretical Domains Framework (TDF)[36] and the capa-
bility, opportunity, and motivation-behaviour (COM-B)
system,[37] the results of which will be mapped using the
Behaviour Change Wheel[38] to identify potential interven-
tions for change.
Other priorities
The five remaining priority topics that were identified will
also require further exploration and development. The
‘pharmaceutical care of vulnerable patients’ and the ‘effec-
tive use of [the] community pharmacy workforce’ were
both identified in Prescription for Excellence and as such,
are less likely to be included in the TRiaDS-P programme
because they will receive national attention and develop-
ment.
Patient counselling for prescribed medication is not
entirely dissimilar to the overall priority topic. Effective
consultation management, whether for OTC or prescribed
medicines, relies upon effective communication behaviour
and consultation skills.[39] In 2011, the New Medicines
Service was introduced in England to improve medication
adherence of patients with long-term conditions.[40] No
similar service exists in Scotland (or to our knowledge in
any other country).
The Promotion and Delivery of the Minor Ailment
Scheme (eMAS) was introduced in Scotland in 2006, with
the purpose of providing equity of access to treatment
and advice for common conditions and as a strategy for
reducing demand on higher cost service providers, e.g.
general practitioners (GPs).[41] However, there is evidence
to suggest that the uptake of eMAS in Scotland has been
lower than anticipated with figures suggesting that not all
eligible individuals have registered.[42] However, this topic
was not selected for reasons of political sensitivity and an
ongoing review of the service.
Table 4 Results of Round 3 eDelphi
Round 3 Topic heading Mean (SD)
Interquartile range
25th
50th
(median) 75th
Promoting the appropriate sale and supply of OTC medicines
[Round 1 median score = 7 and Round 2 median score = 7]
7.00 (0.00) 7.00 7.00 7.00
Patient counselling for prescribed medication
[Round 1 median score = 7 and Round 2 median score = 7]
7.00 (0.00) 7.00 7.00 7.00
Promotion and delivery of the Minor Ailment Scheme
[Round 1 median score = 7 and Round 2 median score = 7]
7.00 (0.00) 7.00 7.00 7.00
Pharmaceutical care to promote medication adherence [e.g.
monitored dosage system (MDS) assessment]
[Round 1 median score = 6 and Round 2 median score = 7]
7.00 (0.00) 7.00 7.00 7.00
Pharmaceutical care of vulnerable patients (including high risk,
sheltered housing residents, immigrants, homeless)
[Round 1 median score = 6 and Round 2 median score = 6]
7.00 (0.00) 7.00 7.00 7.00
Effective use of community pharmacy workforce
[Round 1 median score = 6 and Round 2 median score = 6]
7.00 (0.00) 7.00 7.00 7.00
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Conclusions
This prioritisation study was the first step in the TRiaDS-P
programme and adopted a systematic, inclusive, and rapid
(<5 months) approach to identify priorities for community
pharmacy practice improvement in Scotland. By taking a
systematic, stepped approach underpinned by theory to the
identification, development, and evaluation of potential
educational, service and policy interventions for promoting
the appropriate sale and supply of OTC medicines, TRiaDS-P
increases the likelihood of the efficient and effective transla-
tion of knowledge into community pharmacy practice for
improved patient care. This methodology could be used by
other disciplines and in other countries to prioritise and
address their quality improvement agenda.
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1Pharmacy-based minor ailment schemes (MAS) provide
public access to NHS treatment and/or advice (e.g. acne,
diarrhoea) via a pharmacist or pharmacy personnel, or,
where appropriate, to onward referral to other health
professionals.[43]
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